Obstetric Directorate, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Institute of Human Development, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
BJOG. 2017 Aug;124(9):1411-1419. doi: 10.1111/1471-0528.14478. Epub 2016 Dec 26.
To describe the incidence of mechanical prosthetic heart valves (MPHV) in pregnancy in the UK; rates of maternal and fetal complications in this group of women, and whether these vary with the anticoagulation used during pregnancy.
Prospective descriptive population-based study.
All consultant-led maternity units in the UK.
All women with an MPHV who were pregnant between 1 February 2013 and 31 January 2015.
Collection and analysis of anonymous data relating to pregnancy management and outcome, using the UKOSS notification and data collection system.
Maternal death, serious maternal morbidity, poor fetal outcome.
Data were obtained for 58 women giving an estimated incidence of 3.7 (95% CI 2.7-4.7) per 100 000 maternities. There were five maternal deaths (9%); a further 24 (41%) suffered serious maternal morbidity. There was a poor fetal outcome from 26 (47%) pregnancies. Only 16 (28%) women had a good maternal and good fetal outcome. Low-molecular-weight heparin (LMWH) was used throughout pregnancy by 71% of women. Of these, 83% required rapid dose escalation in the first trimester. Monitoring regimens lacked consistency.
This study has estimated the incidence of MPHV in pregnant women in the UK. It includes the largest cohort managed with LMWH throughout pregnancy reported to date. It demonstrates a high rate of maternal death, and serious maternal and fetal morbidity. Women with MPHVs, and their clinicians need to appreciate the significant maternal and fetal risks involved in pregnancy. Care should be concentrated in specialist centres.
High rates of poor maternal and fetal outcomes in pregnant women with mechanical prosthetic heart valves.
描述英国妊娠期间机械性人工心脏瓣膜(MPHV)的发生率;该组女性的母婴并发症发生率,以及这些发生率是否因妊娠期间使用的抗凝剂而异。
前瞻性描述性基于人群的研究。
英国所有顾问领导的产科单位。
2013 年 2 月 1 日至 2015 年 1 月 31 日期间妊娠的所有 MPHV 女性。
使用 UKOSS 通知和数据收集系统收集和分析与妊娠管理和结局相关的匿名数据。
孕产妇死亡、严重孕产妇发病率、不良胎儿结局。
获得了 58 名女性的数据,估计每 100000 例分娩中有 3.7 例(95%CI 2.7-4.7)。有 5 例孕产妇死亡(9%);另有 24 例(41%)患有严重的孕产妇发病率。26 例(47%)妊娠胎儿结局不良。仅有 16 名(28%)女性母婴结局良好。71%的女性在整个孕期使用低分子肝素(LMWH)。其中,83%的女性在孕早期需要快速增加剂量。监测方案缺乏一致性。
本研究估计了英国妊娠妇女 MPHV 的发病率。它包括迄今为止报告的在整个孕期使用 LMWH 管理的最大队列。它表明孕产妇死亡率以及严重的母婴发病率和发病率均很高。患有 MPHV 的女性及其临床医生需要认识到妊娠期间涉及的重大母婴风险。应将护理集中在专科中心。